Recent research has further demonstrated that inhibitors like TAC5 can selectively target endosomal TLRs (TLR3, TLR7, TLR8, and TLR9) to modulate immune responses and potentially treat autoimmune diseases like psoriasis and systemic lupus erythematosus. Here, TLR7 is linked to autoimmune disease.